此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项单独或与其他抗癌药物的GSK5458514的研究

2026年10月1日 更新者:GlaxoSmithKline

1/2阶段的首次乘坐,开放标签,多中心,剂量升级和扩张研究GSK5458514单独靶向T细胞参与者的PSMA或与其他抗癌药物中的其他抗癌药物组合转移性抗性耐药性 - 耐药性耐药性抗性的抗性癌症(MCRPC)

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

85

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M4N 3M5
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Daniel Khalaf
    • Quebec
      • Montreal、Quebec、加拿大、H4A 3J1
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Ramy Saleh
      • Montreal、Quebec、加拿大、H3T 1E2
        • 招聘中
        • GSK Investigational Site
        • 首席研究员:
          • April Rose
        • 接触:
        • 接触:
      • Kanagawa、日本、232-0024
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Takashi Kawahara
      • Tokyo、日本、104-0045
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Tatsunori Shimoi
      • Tokyo、日本、135-8550
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Yuji Miura
      • Lyon、法国、69373
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Armelle Vinceneux
      • Villejuif、法国、94805
        • 招聘中
        • GSK Investigational Site
        • 首席研究员:
          • Yohann Loriot
        • 接触:
        • 接触:
    • Arizona
      • Phoenix、Arizona、美国、85054
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 首席研究员:
          • Yousef Zakharia
        • 接触:
    • Colorado
      • Denver、Colorado、美国、80218-1234
        • 招聘中
        • GSK Investigational Site
        • 首席研究员:
          • Gerald Falchook
        • 接触:
        • 接触:
    • Connecticut
      • New Haven、Connecticut、美国、06510
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Daniel Petrylak
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Dan Childs
    • New Jersey
      • East Brunswick、New Jersey、美国、08816
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Bruno Fang
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Benjamin Garmezy
      • Badajoz、西班牙、06080
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Marta González Cordero
      • Barcelona、西班牙、08023
        • 招聘中
        • GSK Investigational Site
        • 首席研究员:
          • Tatiana Hernandez
        • 接触:
        • 接触:
      • Madrid、西班牙、28040
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Bernard Doger
      • Madrid、西班牙、28050
        • 招聘中
        • GSK Investigational Site
        • 首席研究员:
          • Emiliano Calvo Aller
        • 接触:
        • 接触:
      • Málaga、西班牙、29010
        • 招聘中
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Lucia Oliva Fernandez
      • Pozuelo de AlarcOn Madr、西班牙、28223
        • 招聘中
        • GSK Investigational Site
        • 首席研究员:
          • VALENTINA BONI
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Provide signed informed consent. Participants must be capable of providing informed consent, which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol.
  • Male participants greater than equal to (>=)18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.

Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 195 days, after the last dose of study intervention:

Refrain from donating sperm

PLUS either:

Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

OR

Must agree to use contraception as detailed below:

Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.

  • Participants with mCRPC:

    • Histologically or cytologically confirmed adenocarcinoma of the prostate
    • Metastatic disease diagnosed either by radiologic imaging (Positron emission tomography [PET]- Computed tomography [CT]) and/or regular CT and/or Magnetic resonance imaging (MRI) and/or bone scan
    • Castration-resistant status as per PCWG3 criteria
  • Has prior novel anti-androgen receptor therapy failure and had treatment failure with 1-2 taxane-based chemotherapy regimens including for metastatic hormone sensitive prostate cancer.

  • Has (1) at least 1 soft tissue target lesion per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) OR (2) if Non-Target soft tissue disease only per PCWG3-modified RECIST 1.1, may be included if a rise in Prostate-specific antigen (PSA) on 2 successive determinations at least 1 week apart (the most recent screening measurement must have been >= 2 nanograms per milliliter (ng/mL) with testosterone levels <50 nanograms per deciliter (ng/dL), OR (3) bone disease defined by PCWG3 (2 or more lesions on bone scan at screening), as determined by the investigator.

  • Documented disease progression on most recent systemic anti-cancer therapy defined by fulfilling at least 1 of the PCWG3 criteria

  • Have serum testosterone <50 ng/dL (<1.7 nM). Patients must have undergone bilateral orchiectomy or be on continuous androgen-deprivation therapy with a Gonadotropin-releasing hormone (GnRH) agonist or antagonist; this therapy must have been initiated at least 4 weeks prior to randomization and treatment must be continued throughout the study.

  • Eastern Cooperative Oncology Group (ECOG) performance status <=1, with no deterioration in the 2 weeks before step-up treatment period Day 1.

  • Have supplied tumor tissue from a newly obtained biopsy or archival tumor tissue for retrospective detection of Prostate-specific membrane antigen (PSMA) expression and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue preferably taken after the completion of the participant's last line of therapy prior to the first dose of study drug is acceptable.

  • Participants must have adequate organ function

Exclusion criteria:

  • Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any histology different from adenocarcinoma.

  • History of central nervous system (CNS) metastases or leptomeningeal disease.

  • Diagnosis of invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, except as noted below:

    • History of an invasive malignancy for which the participant was definitively treated, and in which the participant has been disease free for at least 2 years, and which, in the opinion of the principal investigator and medical monitor, is not expected to affect the evaluation of the effects of the study intervention on the currently targeted disease under study
    • Curatively treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, and/or in situ breast cancer may be enrolled
  • Has ongoing adverse reaction(s) from prior therapy that have not recovered to <=Grade 1 or to the baseline status preceding prior therapy, excluding [e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy], or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.

  • Confirmed history or recurrent autoimmune disease that has required systemic treatments in the 2 years prior to screening. Participants with prior history of autoimmune disease must be discussed with the medical monitor. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary).

  • Has evidence of interstitial lung disease, non-infectious pneumonitis, and/or a history of interstitial lung disease, non-infectious pneumonitis that required steroid.

  • Has received any anti-cancer therapy or prior systemic biologic therapy, including immunotherapy within 30 days prior to first dose of study intervention.

  • Prior PSMA radionuclide therapy within 2 months prior to GSK5458514 unless participant received <2 cycles.

  • Prior PSMA-Chimeric antigen receptor T cell therapy (CAR-T) cell therapy and PSMA (T cell engager) TCE/ Bispecific T cell engagers (BiTE) or other prostate Tumor-associated antigens (TAA) specific T cell engager (TCE).

  • Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.

  • Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • History of severe neurological or psychiatric disorder, including epilepsy, dementia, or major depression deemed to interfere with study assessments.

  • Has had any major surgery (such as craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks prior to first dose of study intervention.

  • Serious infections within 4 weeks prior to the first dose, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for >=2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first dose or oral antibiotics within 1 week prior to the first dose. Participants who are receiving or have received prophylactic antibiotics (e.g., prophylaxis against urinary infections) are allowed.

Liver safety exclusion criteria:

  • Has an Alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or >5x ULN if documented history of liver metastases.
  • Has a total bilirubin value >1.5x ULN.
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Has documented presence of Hepatitis B surface antigen (HBsAg), at screening or within 3 months prior to the first dose of study intervention.
  • Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to Cycle 1 Day 1 unless the participant can meet the following criteria: NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria
  • Has a positive HCV ribonucleic acid (RNA) test result at screening or within 3 months prior to the first dose of study intervention. NOTE: The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
  • Is unable to adhere to the protocol defined SoA, including requirements for the Follow-up Period of the study, study procedures, restrictions, and requirements as determined by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:第1部分:GSK5458514单一疗法的剂量升级

GSK5458514 will be administered.

实验性的:第2部分:GSK5458514单一疗法的剂量扩展

GSK5458514 will be administered.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
DLT观察期间有剂量限制毒性(DLT)的参与者数量
大体时间:长达28天
长达28天
有不良事件(AES),严重不良事件(SAE)的参与者数量,严重性
大体时间:大约29个月
大约29个月
具有AES的参与者数量导致剂量修改
大体时间:大约29个月
大约29个月

次要结果测量

结果测量
措施说明
大体时间
GSK5458514的浓度从0到T(AUC 0-T)的面积
大体时间:大约32个月
大约32个月
GSK5458514的最大浓度(CMAX)
大体时间:大约32个月
大约32个月
达到GSK5458514的最大浓度(TMAX)的时间
大体时间:大约32个月
大约32个月
针对GSK5458514的抗药物抗体(ADA)的参与者数量
大体时间:大约32个月
大约32个月
ADA对GSK5458514的滴度
大体时间:大约32个月
大约32个月
Prostate-specific Antigen Decrease From Baseline >=50% (PSA50) Response Rate
大体时间:Up to approximately 32 months

PSA50 response rate is defined as percentage of participants with a decrease of >=50% in the PSA concentration from the baseline PSA value, confirmed at least 3 weeks later.

Up to approximately 32 months
Objective Response Rate (ORR)
大体时间:Up to approximately 32 months

ORR is defined as the percentage of participants in the ORR Evaluable set who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) per prostate cancer working group 3 (PCWG3) guidelines as assessed by investigator.

Up to approximately 32 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:GSK Clinical Trials、GlaxoSmithKline

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年6月12日

初级完成 (估计的)

2027年10月26日

研究完成 (估计的)

2028年8月9日

研究注册日期

首次提交

2025年5月22日

首先提交符合 QC 标准的

2025年5月22日

首次发布 (实际的)

2025年5月25日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅